Alkermes, Inc. $ALKS
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-36
RECRUITING7
READOUTS ≤12 MONTHS6
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| OLZ/SAM NCT05303064 |
P3 | Recruiting | Schizophrenia; Bipolar I Disorder | 220 | 2026-09 |
| Vibrance-3 NCT06843590 |
P2 | Active, not recruiting | Idiopathic Hypersomnia | 126 | 2026-11 (+7 mo) |
| Brilliance NT1 NCT07455383 |
P3 | Recruiting | Narcolepsy Type 1 | 150 | 2027-05 |
| Brilliance NT2 NCT07502443 |
P3 | Recruiting | Narcolepsy Type 2 | 176 | 2027-05 |
| ALKS 2680 Dose 1 NCT07540897 |
P3 | Recruiting | Narcolepsy Type 1 | 150 | 2027-06 |
| ALKS 7290 NCT07755410 |
P2 | Recruiting | Attention Deficit Disorder With Hyperactivity (ADHD) | 312 | 2027-07 |
| OLZ/SAM NCT04987229 |
P3 | Enrolling by invitation | Bipolar I Disorder; Schizophrenia | 236 | 2027-09 |
| ALKS 7290 Dose NCT07901179 |
P2 | Recruiting | Major Depressive Disorder (MDD) | 180 | 2028-01 |
| ALKS 2680, 4mg NCT06767683 |
P2/3 | Recruiting | Narcolepsy Type 1; Narcolepsy Type 2 | 786 | 2030-06 (+31 mo) |